Business Wire

IMMERVISION

19.5.2022 15:19:11 CEST | Business Wire | Press release

Share
Immervision Brings Human-Like Vision Capabilities to Halodi Robotics

Immervision , the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, is proud to announce it was chosen by Halodi Robotics to provide their next generation vision system for their humanoid service robot platform, capable of handling both human and computer vision.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005594/en/

Robots are capable of performing a wide variety of tasks that are difficult or dangerous for humans to perform. To intelligently and accurately perform these tasks, they require mobility and the aptitude to explore, understand and function within various environments. For a robot to work autonomously, or problem-solve with human assistance, it requires sensor data to understand the human world and the ability to process the data and respond in a timely manner. The difficulty is that for certain applications, a robot needs to combine both human and machine vision capabilities. While performing independent tasks, machine vision suffices, but when functioning in partnership with a human operator, human vision capabilities are needed, hence, the need for a next generation vision system.

“Robots have incredible potential to expand human capabilities and performance in the real world,” says Nicholas Nadeau, CTO of Halodi Robotics. “Immervision is able to help our EVE service robots create even greater value, by allowing human operators, via a virtual reality (VR) headset, to respond with human intuition capabilities to the anomalies that may arise as robots interact with their dynamic environment.”

Immervision’s next-gen vision system enables machines with both visual systems, for multiple sensors and wiring. Robots can now navigate within hospitals or dangerous workplaces, and the vision system can be customized to the environment and specific tasks. The vision system will enable Halodi Robotics robots to better perceive their environment, collect better quality vision data for AI/ML pipelines, as well as providing an immersive VR experience to the operator of the robots.

“Halodi Robotics approached us when searching for a fast, responsive, and immersive visual system capable of delivering wide-angle visual data simultaneously to both machine and humans,” explains Patrice Roulet Fontani, VP of Technology at Immervision. “Increased responsive speed starts with a high-quality wide-angle lens and with our patented technology and AI algorithms, we are the natural choice to optimize the performance and situational awareness across Halodi Robotics entire vision pipeline.”

Immervision has spent over 20 years adding vision to machines. The company’s vision solutions are deployed into several markets, such as automotive, drones and consumer devices, to ensure whether a robot is picking up an object or performing a specific task, they have optimized hand-eye co-ordination. Immervision’s dewarping algorithm enhances its dual next-gen vision solution, ensuring correct proportions are maintained for the entire image and real-time video for both human and machine vision.

Halodi Robotics already has multiple enterprise customer pilot programs underway in Europe and the U.S. for security, retail and logistics applications, with broader deployment planned for later this year.

About Immervision

With over 20 years of innovation, Immervision creates solutions that see beyond human vision. Its Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. The company invents, customises, and licenses wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. For more information: www.immervision.com .

About Halodi Robotics

Halodi Robotics builds service robots to extend growing workforces in security, retail, logistics, and healthcare. Our roboticists design and develop affordable humanoid robots with the skill to operate in unstructured environments where people and machines must work safely together. Operating in near silence with human strength, our robots enable independent automation for everyday tasks. Halodi Robotics bases our global teams at our Norway headquarters with satellite offices in Canada, Italy, and the U.S. For more information about our mission and career opportunities, go to www.halodi.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release

STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD

Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release

Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to

Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm

SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release

SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye